vs
Side-by-side financial comparison of FRANKLIN STREET PROPERTIES CORP (FSP) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $26.0M, roughly 1.3× FRANKLIN STREET PROPERTIES CORP). FRANKLIN STREET PROPERTIES CORP runs the higher net margin — -28.1% vs -299.9%, a 271.8% gap on every dollar of revenue. On growth, Karyopharm Therapeutics Inc. posted the faster year-over-year revenue change (11.6% vs -8.2%). Over the past eight quarters, Karyopharm Therapeutics Inc.'s revenue compounded faster (1.4% CAGR vs -8.7%).
Franklin Street Properties Corp is a Massachusetts-based real estate investment trust (REIT) in the United States. It primarily invests in, owns, and operates high-quality office properties across major U.S. metropolitan markets, serving corporate tenants across various industry segments, and delivers stable long-term returns via rental income and strategic asset management.
FSP vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0M | $34.1M |
| Net Profit | $-7.3M | $-102.2M |
| Gross Margin | 59.4% | — |
| Operating Margin | -27.9% | -52.4% |
| Net Margin | -28.1% | -299.9% |
| Revenue YoY | -8.2% | 11.6% |
| Net Profit YoY | 14.1% | -232.0% |
| EPS (diluted) | $-0.06 | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0M | $34.1M | ||
| Q3 25 | $27.3M | $44.0M | ||
| Q2 25 | $26.7M | $37.9M | ||
| Q1 25 | $27.1M | $30.0M | ||
| Q4 24 | $28.4M | $30.5M | ||
| Q3 24 | $29.7M | $38.8M | ||
| Q2 24 | $30.8M | $42.8M | ||
| Q1 24 | $31.2M | $33.1M |
| Q4 25 | $-7.3M | $-102.2M | ||
| Q3 25 | $-8.3M | $-33.1M | ||
| Q2 25 | $-7.9M | $-37.3M | ||
| Q1 25 | $-21.4M | $-23.5M | ||
| Q4 24 | $-8.5M | $-30.8M | ||
| Q3 24 | $-15.6M | $-32.1M | ||
| Q2 24 | $-21.0M | $23.8M | ||
| Q1 24 | $-7.6M | $-37.4M |
| Q4 25 | 59.4% | — | ||
| Q3 25 | 60.9% | — | ||
| Q2 25 | 59.9% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 59.7% | — | ||
| Q3 24 | 61.0% | — | ||
| Q2 24 | 64.2% | — | ||
| Q1 24 | 64.7% | — |
| Q4 25 | -27.9% | -52.4% | ||
| Q3 25 | -30.5% | -34.6% | ||
| Q2 25 | -29.2% | -64.3% | ||
| Q1 25 | -78.9% | -110.8% | ||
| Q4 24 | -29.9% | -102.4% | ||
| Q3 24 | -52.4% | -67.8% | ||
| Q2 24 | -68.0% | -65.7% | ||
| Q1 24 | -24.0% | -101.9% |
| Q4 25 | -28.1% | -299.9% | ||
| Q3 25 | -30.5% | -75.2% | ||
| Q2 25 | -29.5% | -98.2% | ||
| Q1 25 | -79.1% | -78.2% | ||
| Q4 24 | -30.0% | -100.8% | ||
| Q3 24 | -52.6% | -82.7% | ||
| Q2 24 | -68.2% | 55.6% | ||
| Q1 24 | -24.2% | -112.8% |
| Q4 25 | $-0.06 | $-7.02 | ||
| Q3 25 | $-0.08 | $-3.82 | ||
| Q2 25 | $-0.08 | $-4.32 | ||
| Q1 25 | $-0.21 | $-2.77 | ||
| Q4 24 | $-0.09 | $-2.33 | ||
| Q3 24 | $-0.15 | $-3.85 | ||
| Q2 24 | $-0.20 | $-2.97 | ||
| Q1 24 | $-0.07 | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $30.6M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $607.0M | $-292.9M |
| Total Assets | $892.9M | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.6M | $60.5M | ||
| Q3 25 | $31.4M | $37.7M | ||
| Q2 25 | $29.4M | $38.7M | ||
| Q1 25 | $30.2M | $38.8M | ||
| Q4 24 | $41.1M | $62.5M | ||
| Q3 24 | $40.9M | $72.8M | ||
| Q2 24 | $30.2M | $84.8M | ||
| Q1 24 | $34.2M | $30.6M |
| Q4 25 | $607.0M | $-292.9M | ||
| Q3 25 | $615.3M | $-269.3M | ||
| Q2 25 | $624.7M | $-238.9M | ||
| Q1 25 | $633.4M | $-205.9M | ||
| Q4 24 | $655.9M | $-186.0M | ||
| Q3 24 | $665.4M | $-159.6M | ||
| Q2 24 | $682.1M | $-132.1M | ||
| Q1 24 | $703.9M | $-169.0M |
| Q4 25 | $892.9M | $108.4M | ||
| Q3 25 | $901.0M | $96.2M | ||
| Q2 25 | $903.2M | $104.9M | ||
| Q1 25 | $916.4M | $127.7M | ||
| Q4 24 | $946.9M | $164.4M | ||
| Q3 24 | $981.5M | $189.5M | ||
| Q2 24 | $1.0B | $214.0M | ||
| Q1 24 | $1.0B | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.8M | $-11.8M |
| Free Cash FlowOCF − Capex | $-12.7M | — |
| FCF MarginFCF / Revenue | -48.6% | — |
| Capex IntensityCapex / Revenue | 63.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-25.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.8M | $-11.8M | ||
| Q3 25 | $8.3M | $-5.9M | ||
| Q2 25 | $-2.9M | $-18.7M | ||
| Q1 25 | $-5.5M | $-39.0M | ||
| Q4 24 | $9.0M | $-25.8M | ||
| Q3 24 | $14.5M | $-19.5M | ||
| Q2 24 | $-648.0K | $-38.5M | ||
| Q1 24 | $-7.1M | $-43.7M |
| Q4 25 | $-12.7M | — | ||
| Q3 25 | $3.0M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-9.9M | — | ||
| Q4 24 | $-16.2M | $-25.9M | ||
| Q3 24 | $8.6M | — | ||
| Q2 24 | $-5.1M | — | ||
| Q1 24 | $-15.8M | $-43.9M |
| Q4 25 | -48.6% | — | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | -21.5% | — | ||
| Q1 25 | -36.7% | — | ||
| Q4 24 | -57.2% | -84.7% | ||
| Q3 24 | 29.1% | — | ||
| Q2 24 | -16.7% | — | ||
| Q1 24 | -50.8% | -132.6% |
| Q4 25 | 63.0% | 0.0% | ||
| Q3 25 | 19.4% | 0.0% | ||
| Q2 25 | 10.7% | 0.0% | ||
| Q1 25 | 16.4% | 0.0% | ||
| Q4 24 | 88.9% | 0.2% | ||
| Q3 24 | 19.6% | 0.0% | ||
| Q2 24 | 14.6% | 0.0% | ||
| Q1 24 | 28.1% | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FSP
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
